From Pan-T-Cell Depletion to Selective Graft Engineering: Progress, Limitations, and Open Questions
This review traces that evolution, from CD34+ selection through αβ/CD19 depletion, naïve (CD45RA+) T-cell depletion, adoptive add-back, and gene-edited donor grafts, evaluated against current in vivo prophylaxis, principally post-transplant cyclophosphamide (PTCy).
Kirsty M. Sharplin, Sorur Moshgelgosha, Gurman Kaur
· Journal of Clinical Medicine · 0 citations